Rigosertib is in clinical development for the treatment of high-risk myelodysplastic syndrome (MDS) in patients who had progressed on, failed to respond to, or relapsed after previous treatment with azacitidine or decitabine. MDS are a group of disorders in which red blood cells, white blood cells, and platelets produced by the bone marrow do not grow and mature normally. MDS are long-term debilitating and life-threatening diseases. MDS can lead to severe anaemia, infections or bleeding and can result in leukaemia (cancer of the white blood cells). MDS patients may require repeated blood transfusions and currently have few treatment options.
Rigosertib is administered intravenously and has been designed to inhibit and block the activity of various proteins that suppresses the growth of cancer cells. If licensed, rigosertib will provide a treatment option for higher-risk MDS patients who had progressed on, failed to respond to, or relapsed after previous treatment with azacitidine or decitabine.